<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Journal of Clinical Practice</journal-id><journal-title-group><journal-title xml:lang="en">Journal of Clinical Practice</journal-title><trans-title-group xml:lang="ru"><trans-title>Клиническая практика</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2220-3095</issn><issn publication-format="electronic">2618-8627</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">634277</article-id><article-id pub-id-type="doi">10.17816/clinpract634277</article-id><article-id pub-id-type="edn">NADEAL</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Case reports</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Клинические случаи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Difficulties in the diagnostics of transthyretin amyloidosis with polyneuropathy: a clinical case description</article-title><trans-title-group xml:lang="ru"><trans-title>Сложности в диагностике транстиретинового амилоидоза с полинейропатией: клинический случай</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1176-4113</contrib-id><contrib-id contrib-id-type="spin">6877-6140</contrib-id><name-alternatives><name xml:lang="en"><surname>Ostapchuk</surname><given-names>Ekaterina S.</given-names></name><name xml:lang="ru"><surname>Остапчук</surname><given-names>Екатерина Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент</p></bio><email>ostapchukes2008@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-8911-2007</contrib-id><contrib-id contrib-id-type="spin">9115-6700</contrib-id><name-alternatives><name xml:lang="en"><surname>Glinin</surname><given-names>Oleg P.</given-names></name><name xml:lang="ru"><surname>Глинин</surname><given-names>Олег Павлович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>Oleg_gli@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-1477-9875</contrib-id><name-alternatives><name xml:lang="en"><surname>Alekseeva</surname><given-names>Julija V.</given-names></name><name xml:lang="ru"><surname>Алексеева</surname><given-names>Юлия Валерьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>pozitivsuper2013@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">The Regional Clinical Hospital № 1, Tyumen</institution></aff><aff><institution xml:lang="ru">Областная клиническая больница № 1, Тюмень</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Tyumen State Medical University</institution></aff><aff><institution xml:lang="ru">Тюменский государственный медицинский университет</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2025-06-24" publication-format="electronic"><day>24</day><month>06</month><year>2025</year></pub-date><pub-date date-type="pub" iso-8601-date="2025-08-01" publication-format="electronic"><day>01</day><month>08</month><year>2025</year></pub-date><volume>16</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>97</fpage><lpage>103</lpage><history><date date-type="received" iso-8601-date="2024-07-13"><day>13</day><month>07</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2025-05-11"><day>11</day><month>05</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Эко-Вектор</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://clinpractice.ru/clinpractice/article/view/634277">https://clinpractice.ru/clinpractice/article/view/634277</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND:</bold> In clinical practice, diagnosing of systemic transthyretin amyloidosis (ATTR-amyloidosis) with the impairment of the nervous and cardiovascular systems became possible due to the accessibility of genetic diagnostics and due to the growth of knowledge on this disease. <bold>CLINICAL CASE DESCRIPTION:</bold> A clinical case is presented of transthyretin amyloidosis, manifesting as polyneuropathy with significant neuropathic pain syndrome, with the development of severe vegetative insufficiency and with the impairment of the cardiovascular system in a 63 years old male. This clinical pattern, developing for 3 years, was associated with multiple encounters of the patient to various specialists — rheumatology physicians, neurosurgery specialists, endocrinologists, neurologists, internists, including surgical interventions in the spinal cord, carotid artery and cardiac vessels. The disease has lead to the development of severe cachexia and incapacitation of the patient. <bold>CONCLUSION:</bold> Taking into consideration that ATTR-amyloidosis manifests with the clinical signs of lesions in various organs and systems, and this is interpreted by the specialists within the framework of their specific field apart from the general etiology of the disease. The patient gets prescribed with multiple examinations and symptomatic medications, which causes a delay in the diagnostics and in setting the correct diagnosis. This clinical case describes the classical form of transthyretin amyloidosis, which, upon timely diagnostics, has its pathogenetic therapy.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование.</bold> В клинической практике диагностирование системного транстиретинового амилоидоза (ATTR-амилоидоз) с поражением нервной и сердечно-сосудистой систем стало возможным благодаря доступности генетической диагностики и увеличению знаний о данной патологии. <bold>Описание клинического случая.</bold> Представлен клинический случай транстиретинового амилоидоза, проявляющегося полинейропатией с выраженным нейропатическим болевым синдромом, развитием грубой вегетативной недостаточности и поражением сердечно-сосудистой системы у мужчины 63 лет. Данной клинической картине, развивавшейся в течение 3 лет, сопутствовали многочисленные обращения пациента к различным специалистам — ревматологам, нейрохирургам, эндокринологам, неврологам, терапевтам, в том числе оперативные вмешательства на спинном мозге, сонной артерии и сосудах сердца. Заболевание привело к выраженной кахексии и инвалидизации пациента. <bold>Заключение.</bold> ATTR-амилоидоз проявляется поражением различных органов и систем, и это воспринимается врачами-специалистами в рамках своей области в отрыве от общей картины заболевания. Пациенту назначаются многочисленные исследования и симптоматические препараты, что вызывает задержку в диагностике и постановке правильного диагноза. Данный клинический случай описывает классическую форму транстиретинового амилоидоза, которая при своевременной диагностике имеет патогенетическое лечение.</p></trans-abstract><kwd-group xml:lang="en"><kwd>transthyretin amyloidosis</kwd><kwd>polyneuropathy</kwd><kwd>vegetative dysfunction</kwd><kwd>orthostatic hypotension</kwd><kwd>clinical case</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>транстиретиновый амилоидоз</kwd><kwd>полинейропатия</kwd><kwd>вегетативная дисфункция</kwd><kwd>ортостатическая гипотензия</kwd><kwd>клинический случай</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Адян Т.А., Поляков А.В. Наследственный транстиретиновый амилоидоз // Нервно-мышечные болезни. 2019. Т. 9, № 4. С. 12–25. [Adyan TA, Polyakov AV. Hereditary transthyretin amyloidosis. Neuromuscular diseases. 2019;9(4):12–25]. doi: 10.17650/2222-8721-2019-9-4-12-25 EDN: NRNWQQ</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Никитин С.С., Бардаков С.Н., Супонева Н.А., и др. Фенотипическая гетерогенность и особенности диагностики транстиретинового амилоидоза с полинейропатией // Нервно-мышечные болезни. 2021. Т. 11, № 3. С. 12–36. [Nikitin SS, Bardakov SN, Suponeva NA, et al. Phenotypic heterogeneity and diagnostic features of transthyretin amyloidosis with polyneuropathy. Neuromuscular diseases. 2021;11(3):12–36]. doi: 10.17650/2222-8721-2021-11-3-12-36 EDN: MSVKOX</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Копишинская С.В. Транстиретиновая семейная амилоидная полинейропатия // Журнал неврологии и психиатрии им. С.С. Корсакова. 2018. Т. 118, № 10. С. 82-89. [Kopishinskaia SV. Transthyretin familial amyloid polyneuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(10):82-89]. doi: 10.17116/jnevro201811810182 EDN: YOYQUP</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Sekijima Y. Recent progress in the understanding and treatment of transthyretin amyloidosis. J Clin Pharm Ther. 2014;39(3):225–233. doi: 10.1111/jcpt.12145</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Vieira M, Saraiva MJ. Transthyretin: A multifaceted protein. Biomol Concepts. 2014;5(1):45–54. doi: 10.1515/bmc-2013-0038</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Гудкова А.Я., Шавловский М.М., Соловьев К.В., и др. Системный транстиретиновый амилоидоз. Санкт-Петербург, 2016. 39 с. [Gudkova AY, Shavlovsky MM, Soloviev KV, et al. Systemic transthyretin amyloidosis. Saint Petersburg; 2016. 39 р. (In Russ.)]</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Adams D, Suhr OB, Hund E, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016;29(1):S14–26. doi: 10.1097/WCO.0000000000000289</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Coelho T, Ines M, Conceicao I, et al. Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. Neurology. 2018;91(21):e1999–e2009. doi: 10.1212/WNL.0000000000006543</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Gundapaneni BK, Sultan MB, Keohane DJ, Schwartz JH. Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2018;25(3):464–468. doi: 10.1111/ene.13510</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Schmidt HH, Waddington-Cruz M, Botteman MF, et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2018;57(5):829–837. doi: 10.1002/mus.26034</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Waddington Cruz M, Benson MD. A review of tafamidis for the treatment of transthyretin-related amyloidosis. Neuro Ther. 2015;4(2):61–79. doi: 10.1007/s40120-015-0031-3</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Waddington Cruz M, Amass L, Keohane D, et al. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid. 2016;23(3):178–183. doi: 10.1080/13506129.2016.1207163</mixed-citation></ref></ref-list></back></article>
